Cisplatin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Cisplatin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
4647
Registered trials
2992
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Cisplatin can convert its Small molecule drug profile and DNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Cisplatin (query alias: cisplatin) |
|---|---|
| Modality / target | Small molecule drug; DNA; DNA inhibitors |
| Highest global status | Approved |
| Originator | HQ Specialty Pharma Corp., Privo Technologies, Inc. |
| Active developers | CSPC Ouyi Pharmaceutical Co., Ltd., Eleison Pharmaceuticals, Inc., Eli Lilly & Co. |
The MCP disease footprint includes Biliary Tract Neoplasms, Squamous Cell Carcinoma of Head and Neck, Malignant Pleural Mesothelioma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07699185 | Phase 2 | Recruiting | 336 | Pathologic Complete Response Rate |
| NCT07700667 | Phase 2 | Not yet recruiting | 120 | Objective Response Rate (ORR) |
| NCT07699757 | Phase 1 | Not yet recruiting | 258 | DLTs |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A phase 1 study of R-GDP–venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18)
Phase 1; n=24; evaluation: Positive. Reported fields: AE = The main adverse events were hematologic symptoms, infection, gastrointestinal symptoms, and fatigue. Rates of febrile neutropenia improved after an amendment introducing mandatory granulocyte colony-stimulating factor.
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
Phase 2; n=126; evaluation: not stated. Reported fields: -; Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) = 65.1 Percentage of participants (95% Confidence Interval, 49.1 - 79.0); -
Neoadjuvant serplulimab combined with cisplatin plus 5-fluorouracil in locally advanced head and neck squamous cell carcinoma: A phase II single-arm trial.
Phase 2; n=17; evaluation: Positive. Reported fields: ORR = 75.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Cisplatin addresses Biliary Tract Neoplasms, Squamous Cell Carcinoma of Head and Neck, Malignant Pleural Mesothelioma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-05-26 | Chosa Oncology partners with Allarity to advance the development of the LiPlaCis program. | Approved | Financial terms not disclosed |
| 2020-06-29 | SMRI will collaborate with Oncology Venture to develop and market LiPlaCis and 2X-111 for the treatment of MBC and glioblastoma, respectively. | Approved | US$30.0M milestones; US$30.0M stated total |
| 2015-01-19 | Eleison Pharmaceuticals Partners with Intelgen (HK) Limited to Develop and Commercialize ILC for the China Market | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combination therapy comprising durvalumab and cisplatin/gemcitabine for use in treating bladder cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
